Skip to main content
. 2020 Feb 27;9(3):558. doi: 10.3390/cells9030558

Figure 4.

Figure 4

Saracatinib prevents TAA-induced liver fibrosis and inhibits αSMA expression in primary hepatic stellate cells (HSCs). (A) Representative real-time RT-PCR analysis of type I collagen, αSMA, and PAI-1 mRNA expression in liver tissues of TAA-injected mice treated with or without saracatinib. * p < 0.05, ** p < 0.01 compared with chow group, # p < 0.05 as compared with the TAA-injected chow group. (B) Representative western blot analysis of αSMA expression in liver tissues of TAA-injected mice treated with or without saracatinib. Data in the bar graph are means ± SEM. ** p < 0.01 compared with the chow group. ## p < 0.01 compared with the TAA-injected chow group. (C) Western blot analysis of αSMA expression in cultured HSCs. Primary HSCs were cultured for 2 h, after which unattached cells and debris were removed by washing. HSCs were further cultured for three, five, and 7 days in DMEM containing 0.5% FBS with or without saracatinib. Data in the graph are represented as the mean ± SEM of three independent measurements. ** p < 0.01 compared with Day 5, ## p < 0.01 compared with Day 7.